Ten Bridge Communications company information, Employees & Contact Information

Alterome Therapeutics to Participate in Upcoming Investor Conferences Business Wire

Capstan Therapeutics Announces Initiation of Phase 1 Trial of Lead In Vivo CAR-T Therapy, CPTX2309, for Treating Autoimmune Disease Business Wire

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 Investing News Network

SOTIO to Present Preclinical Data on Lead Antibody-Drug Conjugates, SOT106 and SOT109, at 2025 AACR Annual Meeting Business Wire

AIRNA Appoints Jacob Elkins Chief Medical Officer Business Wire

Tribune Therapeutics Raises EUR 37 Million for Next-Generation Anti-Fibrotic Therapies Business Wire

AIRNA Appoints Matthew Hawryluk as Chief Business Officer Business Wire

Capstan Therapeutics Presents Preclinical Data on Lead In Vivo CAR-T Candidate, CPTX2309, at American College of Rheumatology (ACR) Convergence 2024 Business Wire

SOTIO Announces Upcoming Poster Presentations at the 2024 SITC Annual Meeting Business Wire

SOTIO Expands ADC Pipeline and Synaffix Collaboration to Develop Two Novel Bispecific Candidates, SOT112 and SOT113 Business Wire

SOTIO Presents New Preclinical Data on Enhanced CAR T-Cell Therapies at AACR Annual Meeting Business Wire

SOTIO Announces First Patient Dosed in Phase 1 Clinical Study of SOT201 for Patients with Solid Tumors Business Wire

AIRNA Raises Oversubscribed $60 Million Financing to Advance New Class of RNA Editing Medicines and Progress Best-in-Class AATD Program into the Clinic Business Wire

SOTIO Unveils Promising Preclinical Data on SOT109, a Next-Gen ADC Targeting Cadherin-17 (CDH17) for Colorectal Cancer Business Wire

RyCarma Therapeutics Announces New Leadership and Company Name, Introduces Program in Heart Failure Business Wire

Epic Bio Named a “Fierce 15” Company by Fierce Biotech Business Wire

Rapport Therapeutics Appoints Chief Financial Officer Business Wire

Rapport Therapeutics Appoints Pioneering Industry Leader John Maraganore to Board of Directors Business Wire

Institute of Molecular and Clinical Ophthalmology Basel Spinout RhyGaze Closes USD 86 Million Series A Round to Further Novel Gene Therapy for Vision Restoration Business Wire

Palleon Pharmaceuticals Recognized as a Fierce Biotech “Fierce 15” Company for 2023 Business Wire

Clasp Therapeutics Presents Comprehensive Preclinical Data Validating First-in-Class Precision T Cell Engager Against p53 Mutant Solid Tumors at SITC Annual Meeting Business Wire

Alterome Doses First Patient in Phase 1 Study of ALTA3263, a Novel Pan-KRAS Dual ON/OFF Inhibitor, in Advanced Solid Tumors Business Wire

ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease Business Wire

Nimbus Therapeutics Announces Closing of Takeda’s Acquisition of TYK2 Subsidiary Business Wire

Verve Therapeutics Announces Pricing of Initial Public Offering Business Wire

Nimbus Therapeutics Announces Expansion of Its Immunology Drug Discovery Pipeline Business Wire

Rampart Bioscience Announces $85M Series A Financing to Develop Novel DNA-Based Medicines with Veteran Team Business Wire

Be Bio and Resilience Announce Strategic Collaboration to Manufacture Engineered B Cells, a New Class of Cellular Medicines Business Wire

Palleon Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of Lead Glyco-Immunology Drug Candidate for Oncology Business Wire

InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury Business Wire

Dunad Therapeutics Appoints Michael Bonney as Chair of Board of Directors Business Wire

InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel Business Wire

Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline Including Multiple Clinical Programs Business Wire

Gamida Cell and Be The Match BioTherapies® Expand Strategic Collaboration Business Wire

Capstan Therapeutics to Present Preclinical Data on Lead In Vivo Chimeric Antigen Receptor (CAR)-T Candidate, CPTX2309, at American College of Rheumatology (ACR) Convergence 2024 Business Wire

Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease Business Wire

Pinteon Therapeutics Announces $3 Million Award from Advanced Technology International to Support Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury Business Wire